Seer Inc. (Class A) (SEER) carries a Roarable Rating of E (Strong Sell) with 30/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 0.20 (DISTRESS RISK (<1.8)) • Piotroski F-Score 5/9
FRED Regime × Technicals: 47% of 52W Range • RSI-14 at 27.4 (OVERSOLD (<32))
Capital intensity & 0% operating margin leave 16 pts on the table
While SEER currently carries a cautious 30/100 (E) rating due to Cash Engine Quality (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.01) and Max Pain ($2.04) forces dealer call-delta covering toward $2.50.
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Seer Inc. (Class A) (SEER) dropped -2.51% to $1.94, trading at 47% of its 52-week range ($1.55 – $2.38). Stretched risk/reward at current multiples (-29% return on capital) under elevated 10-year interest-rate pressure.
REDWOOD CITY, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that the Special Committee of Seer’s Board of Dire
Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that the Special Committee of Seer’s Board of Directors (the "Special Committee") has concluded
REDWOOD CITY, Calif., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that it will report financial results for the thir
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +17.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on SEER today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for SEER. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Seer Inc. (Class A) (SEER) ranks #945 by composite RQD confidence (30/100, grade E) and #649 by equity capitalization ($107.4M). Within this direct 5-issuer industry benchmark cohort, SEER leads on earnings valuation at N/A trailing P/E, while LAB leads on capital efficiency and profitability with -28.7% ROIC and 49.9% gross margin. RPID currently holds the highest overall quantitative score in the immediate peer group at 47/100 (D) compared with SEER at 30/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| SEER
ACTIVE
Seer Inc. (Class A) | E | 30/100 | — | 51.1% | -29.1% | -2.51% | $107.4M | Benchmark Subject |
| QTRX Quanterix Corporation | E | 28/100 | — | 46.8% | -35.0% | +0.80% | $148.7M | /qtrx-vs-seer → |
| LAB Standard BioTools Inc. | D- | 41/100 | — | 49.9% | -28.7% | +0.49% | $244.7M | /lab-vs-seer → |
| HBIO Harvard Bioscience Inc. | D | 44/100 | — | 57.7% | -35.0% | +4.51% | $40.1M | /hbio-vs-seer → |
| RPID Rapid Micro Biosystems Inc. (Class A) | D | 47/100 | — | — | -35.0% | -1.37% | $39.6M | /rpid-vs-seer → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Seer Inc. (Class A) (SEER) reported GAAP revenue of $16.6M (+17.0% vs. FY2024 revenue of $14.2M , and -0.5% cumulative change since FY2023) , GAAP net income of -$73.6M, operating cash flow of -$44.4M, and free cash flow of -$46.2M (+6.9% YoY). On the balance sheet, SEER closed FY2025 with $296.1M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 5/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $16.6M | -$73.6M | -$44.4M | -$46.2M | $296.1M | — |
| FY2024 (FY) | 2024-12-31 | $14.2M | -$86.6M | -$46.1M | -$49.7M | $366.6M | — |
| FY2023 (FY) | 2023-12-31 | $16.7M | -$86.3M | -$59.1M | -$59.1M | — | — |
As of 2026-11-01, Seer Inc. (Class A) (NASDAQ: SEER) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 30/100 at a spot price of $1.94 (-2.51% 1D, market cap $107.4M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, SEER ranks #945 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Laboratory Analytical Instruments), SEER carries a Roarable E (30/100 RQD), trailing P/E of N/A, gross margin of 51.1%, and ROIC of -29.1%. By comparison, QTRX (Quanterix Corporation) holds a E grade (28/100 RQD, P/E N/A, ROIC -35.0%, cap $148.7M) and LAB (Standard BioTools Inc.) posts a D- grade (41/100 RQD, P/E N/A, ROIC -28.7%, cap $244.7M). Among the 5-stock peer group, SEER leads on earnings multiple (N/A) while LAB leads on capital efficiency (-28.7% ROIC).
Per SEER's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001726445), Seer Inc. (Class A) generated $16.6M in revenue (+17.0% YoY), -$73.6M in net income, and -$46.2M in free cash flow against $296.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
SEER last traded at $1.94 (-2.51% on volume of 177,567 shares), positioning the stock -3.48% below its 50-day simple moving average ($2.01) and +1.04% above its 200-day simple moving average ($1.92). Across its 52-week range of $1.55 to $2.38, SEER sits at the 47.0% percentile with a 14-day RSI of 27.4 (OVERSOLD (<32)) and an implied next-earnings move of ±11.3% ($1.72 to $2.16).
Why SEER Stock dropped -2.51% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-29% return on capital) under elevated 10-year interest-rate pressure.